<DOC>
	<DOCNO>NCT01443650</DOCNO>
	<brief_summary>Primary Objective : Injection Site Tolerability Secondary Objectives : - To assess safety profile alirocumab SAR236553 ( REGN727 ) - To assess pharmacokinetic-pharmacodynamic relationship alirocumab SAR236553 ( REGN727 )</brief_summary>
	<brief_title>Injection Site Tolerability , Safety , Pharmacokinetics , Pharmacodynamics Different Single-Dose Treatments Alirocumab SAR236553 ( REGN727 ) Healthy Subjects</brief_title>
	<detailed_description>Total duration subject ( include screen ) approximately 85 day .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Serum LDLC level &gt; 100 mg/dL . Exclusion criterion : Subjects indicate use statins accord criterion Adult Treatment Program ( ATP ) III Guidelines , updated 2004 . Initiation new diet major change previous diet within 4 week prior Screening . Subjects must willing maintain consistent diet duration study . Use medication nutraceutical order alter serum lipid within 4 week prior screen , include limited statin , cholesterol absorption inhibitor , fibrates , niacin , bile acid resin , red yeast rice . Fasting serum triglyceride &gt; 200 mg/dL measure 812 hour fast . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>